Australia markets closed

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
19.72-0.28 (-1.40%)
As of 02:02PM CST. Market open.
Currency in CNY

Valuation measures4

Market cap (intra-day) 6.96B
Enterprise value 8.32B
Trailing P/E 216.64
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.81
Price/book (mrq)1.99
Enterprise value/revenue 3.41
Enterprise value/EBITDA 143.24

Trading information

Stock price history

Beta (5Y monthly) -0.14
52-week change 3-23.55%
S&P500 52-week change 326.14%
52-week high 327.08
52-week low 313.16
50-day moving average 318.12
200-day moving average 320.23

Share statistics

Avg vol (3-month) 32.97M
Avg vol (10-day) 31.63M
Shares outstanding 5347.98M
Implied shares outstanding 6347.98M
Float 8125.51M
% held by insiders 161.55%
% held by institutions 18.96%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.05
Trailing annual dividend yield 30.25%
5-year average dividend yield 40.48
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 413 June 2022
Last split factor 21.8:1
Last split date 318 June 2021

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -1.33%
Operating margin (ttm)13.04%

Management effectiveness

Return on assets (ttm)0.91%
Return on equity (ttm)-0.91%

Income statement

Revenue (ttm)2.44B
Revenue per share (ttm)7.12
Quarterly revenue growth (yoy)-11.30%
Gross profit (ttm)N/A
EBITDA 396.91M
Net income avi to common (ttm)-32.36M
Diluted EPS (ttm)-0.09
Quarterly earnings growth (yoy)-59.60%

Balance sheet

Total cash (mrq)357.34M
Total cash per share (mrq)1.04
Total debt (mrq)1.72B
Total debt/equity (mrq)49.06%
Current ratio (mrq)1.16
Book value per share (mrq)10.18

Cash flow statement

Operating cash flow (ttm)118.12M
Levered free cash flow (ttm)-158.07M